Atlas Trials

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Clinical trial NCT03015896 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03015896
Sponsor
David Bond, MD
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Grade 3a Follicular LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Waldenstrom MacroglobulinemiaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2017-02-14
Primary completion
2026-08-09
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.